InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: hutschi post# 206871

Monday, 03/09/2015 1:30:03 AM

Monday, March 09, 2015 1:30:03 AM

Post# of 346339
looks like we have more PS Targeting here during the Keystone Symposia.

Keystone week has Nagata talking PS Targeting and Paul Martin talking "inflammation and wound healing..." to Lisa Coussens to many interesting topics and speakers. Would be nice if SK can kick off the week tomorrow with some backup support from 3rd parties at the conference and close it out Thursday with another SK speech for the cc.

Lets go Peregrine, how about a new band-aid with some form of PS Targeting agent in the mix for better wound healing?? lots of potential everywhere...


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News